-
平臺(tái)編號(hào)：bio-68172
-
國(guó)際編號(hào)：CRL-2516?
-
細(xì)胞信息： CL37
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
CL37
ATCC Number：CRL-2516?
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：0.1ml Designations: CL37
Depositors: ?C Smith
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E.
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:The antibody reacts with human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E. The antibody reacts, immunohistochemically, with rat pulmonary endothelial cells pretreated with tumor necrosis factor alpha (TNF-alpha). CL37 antibody does not block in vitro adherence of neutrophils to TNF alpha-treated endothelial cells and the killing of TNF alpha-treated rat endothelial cells by phorbol ester activated neutrophils [PubMed: 1717513]. For antibody capable of blocking these activities see ATCC CRL-2515 (CL3).
Animals were immunized with human umbilical vein endothelial cells (HUVEC) that had been stimulated with recombinant interleukin-1 (IL-1).
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Maintain cell density between 5 X 10(4) and 1 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 47313: Mulligan MS, et al. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J. Clin. Invest. 88: 1396-1406, 1991. PubMed: 1717513
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：0.1ml Designations: CL37
Depositors: ?C Smith
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E.
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:The antibody reacts with human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E. The antibody reacts, immunohistochemically, with rat pulmonary endothelial cells pretreated with tumor necrosis factor alpha (TNF-alpha). CL37 antibody does not block in vitro adherence of neutrophils to TNF alpha-treated endothelial cells and the killing of TNF alpha-treated rat endothelial cells by phorbol ester activated neutrophils [PubMed: 1717513]. For antibody capable of blocking these activities see ATCC CRL-2515 (CL3).
Animals were immunized with human umbilical vein endothelial cells (HUVEC) that had been stimulated with recombinant interleukin-1 (IL-1).
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Maintain cell density between 5 X 10(4) and 1 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 47313: Mulligan MS, et al. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J. Clin. Invest. 88: 1396-1406, 1991. PubMed: 1717513
